$ARYD News
Last published 2y ago
- 2y agoADGMARYDAdagio Medical Provides Business UpdatesBusiness WireAdagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company")), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business
- 2y agoARYDAdagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac ArrhythmiasBusiness WireBusiness combination transaction with ARYA Sciences Acquisition Corp IV, a special purpose acquisition company sponsored by an affiliate of Perceptive Advisors, closed on July 31, 2024 Publicly traded company
- 2y agoARYDGNTAGenenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderGlobeNewswireMILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to
- 2y agoARYDAdagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesPR NewswireAdagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, and ARYA...
- 2y agoARYDAdagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesPR NewswireAdagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, and ARYA...
- 4y agoARYDFOLDARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus' Gene Therapy Business Due to Market ConditionsGlobeNewswireNEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD) ("ARYA IV"), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it
- 4y agoARYDDISCAFTSIKORMoore Kuehn Encourages KOR, DISCA, FTSI, and ARYD Investors to Contact Law FirmPR NewswireNEW YORK, Nov. 30, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to sha
- 5y agoARYDNOTVTGPXLRNMoore Kuehn Encourages NOTV, ARYD, XLRN, and TGP Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair t
- 5y agoARYDFOLDAmicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: "Caritas Therapeutics"GlobeNewswireBusiness Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding Will Transform Amicus into a Premier Global Comme
- 5y agoARYDARYA Sciences Acquisition Corp IV Announces Pricing of $130 Million Initial Public OfferingGlobeNewswireNEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (the “Company”), a special purpose acquisition company formed for the purpose of entering into a combination with one or...